Australia's Emyria climbs as co partners with trauma psychiatric service

Emyria

07/03/2023 24:25

** Shares of Emyria Ltd  EMD.AX  climb as much as 10% to
A$0.195, set for best day since Feb 16, if gains hold 
    ** The biopharmaceutical developer announces collaboration
with the Pax Centre (PAX), which is Australia's psychiatrist-led
clinical service specialising in complex trauma treatment
    ** Co says collaboration to develop a scalable care
programme for the safe provision of MDMA-assisted therapy for
patients with treatment-resistant post-traumatic stress
disorder(PTSD)
    ** Says under agreement, PAX will provide specialist
psychiatrists and facilities while co will manage clinical trial
design
    ** Stock at its highest level since March 1
    ** Stock up 4.4% this year, as of last close
 

 (Reporting by Ayushman Ojha in Bengaluru)
 ((Ayushman.ojha@thomsonreuters.com;))